Head-to-head evidence
Agalsidase beta vs Migalastat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Fabry Disease
Shared mechanism: Alpha-galactosidase A (GLA / α-Gal A) · full Fabry Disease pipeline
Agalsidase beta · Fabrazyme
Marketed by Sanofi
NCT00837824 · Phase 2 · terminated
This study was randomized but not blinded, had no placebo control, and was terminated early after enrolling only a sixth of its planned patients; with just one clinical event recorded across both dose groups, it could not produce a meaningful comparison of Fabrazyme's effect on disease progression.
Migalastat · Galafold
Marketed by Amicus Therapeutics and partners
NCT00304512 · Phase 2 · completed
This was a very small, unblinded study with only 2 to 4 patients per dose group and no placebo or comparator arm, so while no participant experienced a severe side effect, the study is too small and uncontrolled to demonstrate the drug's efficacy.
Next expected readout: December 2026 · NCT04020055 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Agalsidase beta's landscape · Migalastat's landscape